Effectiveness of BNT162b2 COVID-19 Vaccination in Children and Adolescents.
Обработка статьи · этапы, ошибки и управление
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Klein Nicola P, Demarco Maria, Fleming-Dutra Katherine E, Stockwell Melissa S, Kharbanda Anupam B, Gaglani Manjusha, Rao Suchitra, Lewis Ned, Irving Stephanie A, Hartmann Emily, Natarajan Karthik, Dalton Alexandra F, Zerbo Ousseny, DeSilva Malini B, Konatham Deepika, Stenehjem Edward, Rowley Elizabeth A K, Ong Toan C, Grannis Shaun J, Sloan-Aagard Chantel, Han Jungmi, Verani Jennifer R, Raiyani Chandni, Dascomb Kristin, Reese Sarah E, Barron Michelle A, Fadel William F, Naleway Allison L, Nanez Juan, Dickerson Monica, Goddard Kristin, Murthy Kempapura, Grisel Nancy, Weber Zacharay A, Dixon Brian E, Patel Palak, Fireman Bruce, Arndorfer Julie, Valvi Nimish R, Griggs Eric P, Hallowell Carly, Embi Peter J, Ball Sarah W, Thompson Mark G, Tenforde Mark W, Link-Gelles Ruth
Аннотация
METHODS: Using VISION Network records from April 2021 to September 2022, we conducted a test-negative, case-control study assessing VE against COVID-19-associated emergency department/urgent care (ED/UC) encounters and hospitalizations using logistic regression, conditioned on month and site, adjusted for covariates.
RESULTS: We compared 9800 ED/UC cases with 70 232 controls, and 305 hospitalized cases with 2612 controls. During Delta, 2-dose VE against ED/UC encounters at 12 to 15 years was initially 93% (95% confidence interval 89 to 95), waning to 77% (69% to 84%) after ≥150 days. At ages 16 to 17, VE was initially 93% (86% to 97%), waning to 72% (63% to 79%) after ≥150 days. During Omicron, VE at ages 12 to 15 was initially 64% (44% to 77%), waning to 13% (3% to 23%) after ≥150 days; at ages 16 to 17 VE was 31% (10% to 47%) during days 60 to 149, waning to 7% (-8 to 20%) after 150 days. A monovalent booster increased VE to 54% (40% to 65%) at ages 12 to 15 and 46% (30% to 58%) at ages 16 to 17. At ages 5 to 11, 2-dose VE was 49% (33% to 61%) initially and 41% (29% to 51%) after 150 days. During Delta, VE against hospitalizations at ages 12 to 17 was high (>97%), and at ages 16 to 17 remained 98% (73% to 100%) beyond 150 days; during Omicron, hospitalizations were too infrequent to precisely estimate VE.
CONCLUSIONS: BNT162b2 protected children and adolescents against mild to moderate and severe COVID-19. VE was lower during Omicron predominance including BA.4/BA.5, waned after dose 2 but increased after a monovalent booster. Children and adolescents should receive all recommended COVID-19 vaccinations.